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tumor specificity without compromising
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Abstract
Background: Colorectal cancer is often a deadly disease and cannot be cured at metastatic stage. Oncolytic
adenoviruses have been considered as a new therapeutic option for treatment of refractory disseminated cancers,
including colorectal cancer. The safety data has been excellent but tumor transduction and antitumor efficacy
especially in systemic administration needs to be improved.
Methods: Here, the utility of avb integrin targeting moiety Arg-Gly-Asp (RGD) in the Lys-Lys-Thr-Lys (KKTK) domain
of the fiber shaft or in the HI-loop of adenovirus serotype 5 for increased tumor targeting and antitumor efficacy
was evaluated. To this end, novel spleen-to-liver metastatic colorectal cancer mouse model was used and the
antitumor efficacy was evaluated with magnetic resonance imaging (MRI).
Results: Both modifications (RGD in the HI-loop or in the fiber shaft) increased gene transfer efficacy in colorectal
cancer cell lines and improved tumor-to-normal ratio in systemic administration of the vector.
Conclusions: Antitumor potency was not compromised with RGD modified viruses suggesting increased safety
profile and tumor specificity.
Background
Colorectal cancer is the fourth most common type of
cancer in men and the third most common in women
worldwide and more than one million people are diag-
nosed with colorectal cancer every year. Incidence rates
have increased during past decades, while 5-year survival
rates have improved but remain between 60 to 40% in
different countries [1,2]. Metastatic disseminated disease
can be cured only rarely and even though early detec-
tion and prevention strategies play a key role in improv-
ing colorectal cancer statistics, also new therapeutic
options are needed. To this end, gene therapy has been
of interest to cancer researchers for a few decades and
modalities based on adenovirus serotype 5 vectors are
one of the most studied strategies. Safety data for ade-
novirus 5 has been excellent [3-6] and some recent clin-
ical studies have shown some evidence of efficacy for
many types of cancer[3-8] including colorectal cancer
[9,10]. However, the main disadvantage of the current
adenoviral therapies is that the efficacy of tumor trans-
duction limits the efficacy of treatment. In particular,
intravenous administration of the vector does not
usually allow transduction levels compatible with clinical
responses [11,12].
Thus, for successful cancer gene therapy, tumor trans-
duction efficiency needs to be improved, in particular if
systemic administration is the goal. Intravenous
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administration of unmodified adenovirus 5 vectors to
mice leads mainly to infection of liver cells. This is
mostly due to natural engulfment of adenoviral particles
by hepatic macrophages (mainly Kupffer cells) [13] but
also several blood factors have been suggested to be
involved by bridging the viral capsid proteins to heparan
sulphate proteoglycans (HSPG) and some other receptor
molecules on the surface of hepatocytes [14-20]. There-
fore several attempts have been made to detarget the
liver for more appealing systemic bioavailability. Cox-
sackie- and adenovirus receptor (CAR) binding ablation
by changing amino acid residues of the fiber binding
motif has been suggested to avoid vector ending into
the liver hepatocytes but this modification has been
shown to be an inadequate to change the biodistribution
of the virus [21]. Cell surface integrins are also impor-
tant players in the adenovirus serotype 5 entry. After
binding to CAR, adenoviral penton base Arg-Gly-Asp
(RGD) motif interacts with cellular avb integrins to
facilitate internalization [22,23]. However, even double
ablation of CAR and integrins fail to reduce Ad5 hepa-
tocyte tropism in systemic delivery [21,24-27]. In the
absence of CAR, Lys-Lys-Thr-Lys (KKTK) domain in
the fiber shaft has been suggested to play a major role
in viral internalization via low affinity binding with
HSPG [27-29] and a mutation in this domain has been
shown to decrease viral tropism towards hepatocytes
[27,29].
It has been shown earlier with replication deficient
viruses that in comparison with unmodified virus,
increased tumor cell transduction is achieved with ade-
noviruses with RGD moieties in the HI loop of the fiber
or in the KKTK domain of the fiber [30]. Furthermore,
mutation of the KKTK domain ablated binding to
HSPGs and led to reduced liver cell transduction and
improved tumor-to-liver transduction ratio [30]. We
hypothesize here that the antitumor efficacy of systemi-
cally administered replicating competent adenovirus can
be increased by targeting virus towards cell surface avb
integrins and by simultaneously abrogating liver trans-
duction with mutated KKTK domain of the fiber shaft.
To this end, novel spleen-to-liver metastatic colorectal
cancer mouse model was used and the antitumor effi-
cacy was evaluated with magnetic resonance imaging
(MRI).
Methods
Cell lines
All human colorectal cancer cell lines were acquired
from ATCC (American Type Culture Collection), cul-
tured in the recommended growth media with 10% fetal
calf serum (FCS) and maintained in a humidified atmo-
sphere at 37°C and 5% CO2.
Viruses
Non-replicating viruses were produced by substitution of
the E1 region for a marker gene cassette. All non-repli-
cating viruses contain a green fluorescent protein (GFP)
and a firefly luciferase (Luc) expression cassette under
the constitutive cytomegalovirus promoter replacing E1.
For all non-replicating viruses, cloning and large-scale
production has been described before (see Table 1 for
references). Replication competent viruses WT-RGD and
WT-RGDK were kindly provided by Professor Ramon
Alemany (Translational Research Laboratory, Institut
d’Investigació Biomèdica de Bellvitge (IDIBELL)-Institut
Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona,
Spain). A summary of all viruses is given in Table 1.
Animals
All animal experiments were conducted according to the
rules set by the Provincial Government of Southern Fin-
land (permit number ESLH-2008-01986/Ym-23). Patho-
gen-free, 3-4-week-old female NMRI nude mice were
purchased from Taconic (Ejby, Denmark) and quaran-
tined for 2 weeks. The animals were fed ad libitum and
maintained in a HEPA-filtered environment with cages,
food, and bedding sterilized by autoclaving.
Analysis of the transgene expression
Cells were infected with replication deficient, luciferase-
expressing viruses at 1000 viral particles per cell (VP/
cell) in 200 μl of 2% FCS for 30 min, and then washed
and incubated with complete growth medium at 37°C.
After 24 h, luciferase assay (Luciferase Assay System,
Promega, Madison, WI, USA) was performed according
to the manufacturer’s instructions.
Viral oncolytic potency in human colorectal cancer cells
Cells were infected with replication competent viruses
or non-replicating control virus, and after 1 h, infection
medium was replaced with medium containing 5% FCS,
which was changed thereafter every other day. 8 to 11
days later (at the optimal time point for each cell line),
cell viability was analyzed with the mitochondrial activ-
ity-based 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl) -2-(4-sulfophenyl)-2H- tetrazolium
(MTS) assay (Cell Titer 96 AQueous One Solution Cell
Proliferation Assay; Promega, Stockholm, Sweden).
Spleen-to-liver tumor model
The surgical procedure was similar to what has been
previously described [31]. Briefly, mice were anesthe-
tized with ketamine (Ketaminol® 75 mg/kg; Intervet,
Boxmeer, Netherlands)/dexmedetomidine (Dexdormitor®
1 mg/kg; Orion Pharm, Espoo, Finland) admixture and
the spleen was exteriorized through a left lateral flank
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incision. Tumors were established by intrasplenic injec-
tion of 2 × 10e6 HCT116 cells suspended in 50 μl of
serum-free growth media using a 27-gauge needle. The
injection site of the spleen was pressed with a cotton
stick wet in iodine-polividone solution (Betadine®; Leiras,
Helsinki, Finland) in order to remove extravasated cells
and ensure hemostasis. The peritoneum and skin were
closed in a single layer using surgical thread. Finally, ati-
pamezole (Antisedan® 1 mg/kg; Orion Pharm, Espoo,
Finland) was injected subcutaneously to reverse
anesthesia.
Biodistribution study
21 days after intrasplenic injection of HCT116 cells, 3 ×
10e10 VP of AdTL, AdTLGR, or AdTLRGDK in 150 μl
of PBS were injected through the tail vein of NMRI
nude mice. After 48 hours, mice (n = 5 in each group)
were sacrificed and organs and tumors were harvested
for luciferase analysis. To separate between tumors and
organs, tumor tissue and normal liver/spleen tissues
were microdissected by visual inspection. Data was nor-
malized for protein concentration by Pierce BCA Pro-
tein Assay Kit® (Thermo Scientific, Rockford, IL, USA).
Antitumor efficacy in vivo
Tumors were implanted as described above. On days 23
and 24 after cell injection, mice were treated with two
intravenous injections of 3 × 10e10 VP of WT, WT-
RGD, or WT-RGDK in 100 μl volume of PBS (n = 4,
11, and 9, respectively). Mock animals (n = 9) were trea-
ted with PBS only. Tumor volume was followed up by
MRI of the abdomen. Mice were imaged under isoflur-
ane (Baxter, Helsinki, Finland) anesthesia. 30 minutes
before imaging, 1 mg/kg of contrast agent Endorem
(Guerbet, Roissy CdG Cedex, France) in 100 μl volume
was administered intravenously.
MRI studies were performed with a 4.7 T scanner
(PharmaScan, Bruker BioSpin, Ettlingen, Germany)
using a 90-mm shielded gradient capable of producing a
maximum gradient amplitude of 300 mT/m with an 80-
μs rise time. A linear birdcage RF coil with an inner dia-
meter of 38 mm was used. T2-weighted images were
acquired using rapid acquisition with relaxation
enhancement (RARE) sequence (TR/TEeff = 3767/36 ms,
matrix size = 256 × 256, Rare Factor = 8, field-of-view =
33 × 33 mm2, 32 slices, slice thickness = 0.7 mm, num-
ber of averages = 8).
Tumor tissue areas in the liver were measured in
every slice and a total tumor volume was calculated
using the formula: ∑ (Area*slice height) or ∑ (Area*0.7).
In order to distinguish hepatic tumor tissue from vessels
or other structures present in the liver, all images were
compared to a baseline image of each mouse taken
before tumor implantation. Daily volumes of hepatic
Table 1 Description of viruses used in the study
Virus Capsid modification References
Replication deficient virusesa AdTL Wild type 5 capsid
DATL -Y477A substitution in DE loop of fiber knob for CAR ablation
-Penton base’s RGD domain mutated to RGE for avb integrin ablation [41]
-6xhistidine carboxy-terminal tag for the propagation in 293.HissFv.rec cells
AdTLG -Fiber shaft’s KKTK domain mutated to GATK for HSPG ablation [27]
AdTLGR -RGD insertion in HI loop of fiber knob for avb integrin targeting
-Fiber shaft’s KKTK domain mutated to GATK for HSPG ablation [27]
AdTLYG -Y477A substitution in DE loop of fiber knob for CAR ablation
-Fiber shaft’s KKTK domain mutated to GATK for HSPG ablation [21,27]
AdTLYGR -Y477A substitution in DE loop of fiber knob for CAR ablation
-RGD insertion in HI loop of fiber knob for avb integrin targeting
-Fiber shaft’s KKTK domain mutated to GATK for HSPG ablation [21,27]
AdTLY -Y477A substitution in DE loop of fiber knob for CAR ablation [21]
Ad5luc1RGD -RGD insertion in HI loop of fiber knob for avb integrin targeting [42]
AdTLRGDK -Fiber shaft’s KKTK domain mutated to RGDK for avb integrin targeting [30]
-HSPG ablation via mutated KKTK
Replicating viruses WT -Replicating wild type 5 virus
WT-RGD -RGD insertion in HI loop of fiber knob for avb integrin targeting [43]
WT-RGDK -Fiber shaft’s KKTK domain mutated to RGDK for avb integrin targeting [30]
-HSPG ablation via mutated KKTK
aAll replication deficient viruses are deleted for E1A and have both luciferase (Luc) and green fluorescent protein (GFP) as marker genes.
CAR, coxsackie virus and adenovirus receptor; HSPG, heparan sulphate proteoglycan; VP, viral particles; pfu, plaque forming unit.
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tumor tissue were normalized to tumor volume one day
before treatment. The survival of animals was followed.
Viral replication in tumor tissue
29 days after intrasplenic injection of tumor cells, mice
were treated with 3 × 10e10 VP of WT, WT-RGD, or
WT-RGDK in 100 μl of PBS, or PBS alone (mock) (n =
5 in all groups, except for WT-RGDK n = 6). 3 days
after treatment, mice were sacrificed and hepatic tumors
were harvested, homogenized and diluted in growth
media. After three freeze and thaw cycles (-80C/room
temperature), tumor lysates were centrifuged, superna-
tant was collected and added to 293 cells to perform
TCID50 test. Plaque forming units per ml (pfu/ml)
values were normalized for total hepatic tumor volume
and the final result was given as amount of pfu/tumor.
Statistics
All analyses were done with SPSS 15.0 for Windows.
One-way analysis of variance (ANOVA) followed by
Dunnett’s Pairwise Multiple Comparison t-test was used
to analyze the differences in the cell killing potency of
viruses in vitro and tumor growth and virus replication
in vivo. Mann-Whitney test was used to analyze the dif-
ferences in the biodistribution and tumor-to-organ
ratios. Survival data was plotted into a Kaplan-Meier
curve and groups were compared pair-wise with log-
rank test. A value for p < 0.05 was considered statisti-
cally significant.
Results
Gene transfer to human colorectal cancer cells
Six established colorectal cancer cell lines were infected
with a panel of capsid modified viruses and control
virus with an unmodified Ad5 capsid (Figure 1). A
Y447A substitution was engineered into the DE loop of
the fiber knob for CAR binding ablation (AdTLY). This
decreased transgene expression in comparison with Ad5
in all six cell lines confirming the crucial role of CAR in
vitro infection in colorectal cancer cells. Also ablation of
Figure 1 Gene transfer to human colorectal cancer cells. Adenoviral vectors targeted for avb integrins via Arg-Gly-Asp (RGD) modification in
the HI loop (Ad5luc1RGD) or the shaft domain (AdTLRGDK) of the fiber showed enhanced gene transfer to human colorectal cancer cell lines.
Cells were infected with 1000 VP/cell and luciferase activity was measured 24 hours later. Data is presented as relative light units (RLU)
normalized for gene expression of Ad5 control virus AdTL. Each data point represents the mean of three replicates ± SEM.
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binding to HSPG (AdTLG) reduced gene transfer com-
pared to Ad5. As expected, double ablations for CAR
and avb integrin (DATL) or CAR and HSPG (AdTLYG)
binding reduced gene expression levels as well. Since
CAR/HSPG ablation affects significantly the ability of
viruses to infect 293 cells, the usual assessment of pfu
titers cannot be performed. Therefore, a direct compari-
son of VP to pfu ratios between viruses cannot be done
and it is possible that some of the differences observed
between the groups are due to variable viability of viral
preparations.
Targeting viruses to cell surface avb integrins by
inserting RGD tripeptide motif into the HI loop of the
fiber knob (Ad5lucRGD) or into the fiber shaft KKTK
domain (AdTLRGDK) increased the expression of trans-
gene in all tested cell lines in comparison with AdTL.
Interestingly, the optimal location for the RGD modifi-
cation in the fiber varied between cell lines. In HCT116
and HT29 cells, RGD in the HI loop of the fiber was
the most potent and increased luciferace expression 145
and 804 -fold in comparison with the wild type virus,
respectively. In Co115 and CaCo-2 cells, the highest
gene expression levels were displayed by the virus with
the RGD in the HSPG binding ablated fiber shaft (22
and 192 fold increase, respectively). For two cell lines
(SW480 and SW620), both RGD variants were equally
effective. The RGD mediated enhancement in transgene
expression was partially abolished by introducing addi-
tional modification(s) in the fiber to ablate binding
either from HSPG (AdTLGR) or from both HSPG and
CAR (AdTLYGR). In five out of six cell lines, RGD
modification in the HI loop increased transduction effi-
ciency in comparison with control virus even if the vec-
tor interaction with CAR and HSPGs was abrogated
(AdTLYGR).
Biodistribution of adenoviral vectors with RGD
modification in the capsid
Since avb integrin targeted vectors showed an increased
transduction efficacy in colorectal cancer cells in vitro,
the biodistribution of RGD modified viruses in vivo was
tested in metastatic colorectal cancer spleen-to-liver
model. In addition to tumor targeting RGD moieties,
viruses had also a mutated KKTK domain of the fiber
shaft, which has been shown earlier to decrease viral
tropism towards hepatocytes [27]. NMRI nude mice
bearing intrasplenic and intrahepatic HCT116 tumors
were systemically injected with 3 × 10e10 VP of AdTL
(Ad5 control), AdTLGR (RGD in the HI loop; KKTK
mutated to GATK), or AdTLRGDK (KKTK mutated to
RGDK) (Figure 2A). At 48 hours, luciferase activity and
protein concentration of organs and tumors (primary
spleen tumors and metastatic liver tumors) were mea-
sured. The best tumor transduction was achieved with
AdTLRGDK, which displayed the highest transgene
expression in both spleen tumors and liver metastases.
For spleen tumors, transgene expression of AdTLRGDK
was significantly higher in comparison with AdTLGR
virus (p = 0.047) and the similar trend was seen in com-
parison with the Ad5 control. In the liver tumors, no
statistically significant differences were seen between
viruses due to low number of tumors in each treatment
group (n = 2, 2, and 1 for AdTL, AdTLGR, and
AdTLRGDK, respectively). Both RGD modified viruses
showed an increased tumor-to-normal ratio in transgene
expression (Figures 2A and 2B). Virus with RGD modifi-
cation in the HI loop (AdTLGR) increased tumor cell
transduction in the spleen and liver tumors 6 (p =
0.025) and 4 fold in comparison with unmodified virus,
respectively. Similarly, virus with RGD modification in
the KKTK domain of the fiber shaft (AdTLRGDK)
increased spleen and liver tumor transduction 6 and 5
fold, respectively.
Interestingly, AdTLRGDK and AdTLGR viruses
showed significant differences in their biodistribution. In
the normal liver tissue, AdTLGR displayed significantly
lower transgene expression if compared to AdTL (p =
0.047), whereas AdTLRGDK showed significantly higher
expression in comparison with AdTL (p = 0.047). A
similar trend was seen in the spleen, where AdTLGR
demonstrated lower gene transfer in comparison with
AdTL (p = 0.014), but the difference between
AdTLRGDK and AdTL was not significant (p = 0.14).
For kidneys and lungs, the only statistically significant
difference was enhanced gene transfer of AdTLGR in
comparison with AdTL (p-values of 0.047 and 0.027,
respectively). In the heart, no significant differences in
the efficacy of gene transfer were seen between viruses.
Cell killing potency of RGD modified viruses in vitro
Oncolytic potency of replication competent viruses WT-
RGD, WT-RGDK, and control virus WT was analyzed
in six colorectal cancer cell lines in vitro by MTS assay
(Figure 3). At the lowest viral dose (0.1 VP/cell), RGD
modified viruses killed cells more effectively in compari-
son with WT in three out of six cell lines. At higher
viral doses, however, RGD insertion in the HI loop of
the fiber (WT-RGD) or in the shaft domain (WT-
RGDK) did not increase the oncolytic potency and all
three replication competent viruses showed an equal cell
killing potency in all six established colorectal cancer
cell lines. The E1-deleted Ad5 control virus did not
cause oncolytic cell death in any of the cell lines.
Antitumor efficacy of RGD modified viruses in the spleen-
to-liver colorectal cancer model
Colorectal cancer cells (HCT116) were injected into the
spleen of NMRI nude mice and intrasplenic and hepatic
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tumors were allowed to grow for 23 days. Two intrave-
nous injections of viruses were given on consecutive
days, and hepatic tumor volumes were followed by MRI
thereafter (Figure 4A). By day 21, the growth rate of
hepatic tumors was inhibited in all virus treated groups
if compared to mock treated animals. At the end of the
experiment on day 35, only WT-RGD (p = 0.004) and
WT-RGDK (p = 0.026) treated animals showed statisti-
cally significant reduction in tumor growth in
comparison with mock animals, while borderline signifi-
cance (p = 0.054) was observed between WT and mock
groups. Treatment with WT, WT-RGD and WT-RGDK
led to median survival of 44.5, 41, and 46 days, respec-
tively, while median survival for mock treated animals
was 28 days (Figure 4B). In comparison with mock,
none of the treatments improved survival statistically
significantly. However, three of the mice treated with
WT-RGDK virus survived 15, 16, and 36 days longer
Figure 2 Biodistribution of adenoviral vectors with RGD modification in the capsid. Mice bearing intrasplenic and intrahepatic tumors
were injected via tail vein with 3 × 10e10 VP and organs/tumors were harvested two days later. The number of 5 animals was treated in each
group. (A) Luciferase expression of organs was analyzed. Data are presented as relative light units (RLU) after normalization for protein
concentration. Each bar represents mean ± SEM. (B) Spleen tumor to normal spleen ratio of transgene expression. (C) Liver tumor to normal liver
ratio of transgene expression. *, p < 0.05; **, p < 0.01.
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than the last mouse in the mock group (p = 0.055
between mock and WT-RGDK). Typical results of MRI
are presented in Figure 5.
Viral replication in the liver tumors
Hepatic tumors induced by intrasplenic inoculation of
the HCT116 cells were harvested three days after intra-
venous virus administration to assess the amount of
actively replicating virus in the tumors by TCID50
method (Figure 4C). All tumors from virus treated ani-
mals had measurable titers for replicating virus whereas
no virus replication was detected in tumors of PBS trea-
ted mice. However, no statistically significant differences
in the functional titers were observed between different
viruses and active virus was found in all tumors col-
lected from virus treated animals.
Figure 3 Cell killing potency of RGD modified viruses in vitro. Viruses with RGD modification in the capsid display effective killing of
colorectal cancer cell lines. Cells were infected with replication competent (WT-RGD, WT-RGDK, WT) or non-replicating (Ad5luc1) viruses and the
cell killing potency was assessed with the MTS assay. Data are presented as relative cell viability normalized to mock (growth medium) infected
cells. Each data point represents the mean of six replicates ± SEM.
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Discussion
Numerous papers suggest that other entry mechanisms
in addition to CAR binding are important in mediating
adenovirus serotype 5 distribution in vivo [21,32]. Here,
we tested the biodistribution of avb integrin targeted
Ad5 vectors able or unable to bind to HSPG. In line
with an earlier study by Bayo-Puxan et al [27], a virus
with RGD modification in the HI loop and mutation of
the fiber shaft KKTK domain to GATK (the HSPG
binding ablation) showed reduced liver and spleen trans-
duction in comparison with wild type virus. This
demonstrates the potency of mutated KKTK to GATK
in the fiber shaft to detarget the liver in vivo. We used
different tumor cell lines and tumor models than what
had been used in previous reports, suggesting that the
phenomenon is not a cell line or tumor model specific
finding.
It has been suggested earlier, that GATK mutation in
the KKTK domain (AdTLGR) may reduce the potency
of tumor targeting by the RGD modification in the HI-
loop [27]. However, in contrast to earlier findings show-
ing a decreased tumor cell transduction in subcutaneous
A549 xenografts [27], no reduction in liver and spleen
tumors transduction was seen with AdTLGR virus in
comparison with unmodified virus. In the contrary, a
significantly increased tumor to normal spleen gene
delivery ratio was seen with AdTLGR. This suggests
that RGD modification in the HI loop of KKTK mutated
virus might be useful to increase tumor specificity.
However, in our experiments the efficacy of this modifi-
cation varied between cancer cell types and tumor mod-
els used. HCT116 cells are typical representatives of
clinical colorectal cancers [33-35] in that they express
high levels of av integrins [36] which might partially
explain the good transductional targeting achieved with
RGD modified viruses in this study.
KKTK mutation to RGDK might also theoretically
detarget vector from the liver and this has been tested
earlier in C57BL/6 mice [30]. As a result, marginal
decrease in the liver transduction was seen accompanied
by an increase in the tumor cell transduction [30]. In
our model, KKTK domain mutation to RGDK signifi-
cantly increased transgene expression in the liver in
comparison with unmodified virus, and similar trend
was seen in all the other organs as well. This may have
been caused by the opposite effects of HSPG ablation
and RGD insertion; while the former ablates transduc-
tion via HSPG, the latter increases delivery through av
integrins. However, since tumor cell transduction was
increased more than transduction to normal tissue,
increasing trend in tumor-to-organ ratio was seen in
comparison with unmodified virus.
Figure 4 Antitumor efficacy of RGD modified viruses in the
spleen-to-liver colorectal cancer model. Enhanced therapeutic
effect of RGD modified replication competent adenoviruses in
spleen-to-liver colorectal cancer model. To imitate clinical metastatic
colorectal cancer, hepatic tumors were induced in mice by
intrasplenic injection of HCT116 colorectal cancer cells. WT, WT-RGD,
or WT-RGDK viruses at dose of 3 × 10e10 VP were injected via tail
vein in two consecutive days (days 23 and 24). (A) Hepatic tumor
growth was followed with MRI thereafter. Relative tumor volumes
normalized to the day before virus treatment (day -1) tumor
volumes are presented. Each data point represents mean of 2 to 11
measurements ± SEM. *, p < 0.05; **, p < 0.01. (B) The survival of
animals was assessed. No statistically significant differences in the
survival of animals between treatment groups were observed. (C)
Virus replication in liver tumors was assessed three days after
systemic administration. Mock animals received PBS only. Pfu/ml
values obtained from TCID50 test were normalized for tumor
volume. Each dot represents an individual liver tumor. All viruses
replicated in the liver tumor tissue and no statistically significant
differences were seen between virus treated groups.
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Overall, replacing KKTK with RGD in the fiber shaft
emerged as the optimal fiber mutation. As the most rele-
vant control for efficacy experiments, we selected an
established RGD modification of the capsid (KKTK
intact, RGD in HI loop), as this virus has already been
safely used in a clinical trial [37]. In vitro, antitumor effi-
cacy was increased with both RGD modified viruses in
comparison with unmodified virus in 3 out of 6 cell lines.
However, as expected in vitro conditions, where most
viruses are expected to eventually enter cells as they have
no other place to go to, differences were small.
In an advanced orthotopic model of metastatic color-
ectal cancer, tumor growth was significantly reduced by
RGD modified viruses in comparison with untreated
animals. In contrast, the difference between untreated
animals and animals treated with wild type control virus
was not significant. Overall, RGD modification in the
HI-loop or in the KKTK domain of the shaft might be
useful to increase an antitumor efficacy of an oncolytic
adenovirus. However, additional targeting strategies are
needed (e.g. transcriptional targeting) to increase tumor
specificity of these viruses before testing these con-
structs in humans.
In this study, the feasibility of using MRI analysis for
following tumor growth was evaluated. From an ethical
point of view, this method reduces the number of mice
needed in each group since individual tumors inside
body cavity can be followed. MRI allows also the use of
non-subcutaneous tumor models for tumor growth fol-
low-up. Tumors grown in the correct organ likely
resemble the human disease more closely than subcuta-
neous tumor models [38,39]. Therefore, in vivo MRI
analysis for the tumor growth follow-up may emerge as
a valuable tool for future studies.
Figure 5 Viral replication in the liver tumors. The growth of liver metastasis was analyzed with magnetic resonance imaging (MRI). Tumors
are marked with arrows. Picture of liver metastasis of mock treated (PBS) animal (A) 1 day before treatment and (B) on day 35 after treatment.
(C) Picture of liver metastasis of WT-RGD treated animal one day before treatment and (D) on day 35 after WT-RGD treatment.
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Targeting adenovirus towards av integrins is an effec-
tive way to increase tumor cell transduction in vitro, as
was shown by an increased transduction of colorectal
cancer cells with RGD targeted vectors, even if the vec-
tor interaction with CAR and HSPGs was abrogated.
However, in vivo the situation is more complicated. Sev-
eral studies have shown that adenovirus vector targeting
in vivo is not mediated only by vector binding proper-
ties to cell surface receptors and vector biodistribution
does not correlate with in vitro data. This suggests that
many factors, including anatomical barriers [40], vascu-
lar access or blood factors [14-17] play a role in deter-
mining the faith of systemically administered adenoviral
vectors in vivo. Also the use of different animal and
tumor models makes the interpretation and comparison
of results complicated and it is not well understood how
these models correlate with humans. Furthermore, most
of the existing data are based on immune deficient
mouse models and whether it can be applied in humans
where the immune system makes the life of an adeno-
virus much tougher, requires further study.
RGD modification in the KKTK domain of the fiber
shaft may have potential to increase the overall antitu-
mor efficacy of the oncolytic adenovirus. However,
transductional targeting may not be enough to make the
virus usable in humans and therefore additional target-
ing strategies have been utilized. For instance, transcrip-
tional targeting of the virus via tumor specific
promoters or with mutations which are transcomple-
mented by mutations in tumor cells (e.g. 24 bp deletion
in E1A; “D24”) would make the virus more tumor speci-
fic and increase efficacy and safety.
Conclusions
Here, the antitumor potency of RGD modified viruses
was proved to be equal, or marginally increased, in com-
parison with unmodified wildtype 5 virus. In addition,
tumor targeting was improved significantly. These
results suggest that RGD modification increases the spe-
cificity and safety of oncolytic adenovirus without com-
promising the efficacy in an experimental model and
gives rationale for testing the RGD modification in the
context of oncolytic adenoviruses in humans.
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